Century Therapeutics, Inc. (IPSC)

Over the past six months, Century Therapeutics' stock (IPSC) has experienced a stock price increase, with the stock increasing by 130.2% between January 1, 2026, and May 8, 2026. In January 2026, the company completed an oversubscribed $135 million private placement. On March 12, 2026, the company reported its full-year 2025 financial results, highlighting a significant increase in collaboration revenue and a narrowed net loss. Analyst ratings and price targets were maintained with bullish and buy ratings in May 2026, and the price target was increased by 22% on April 22, 2026. On April 30, 2026, Century Therapeutics was selected for an oral presentation of CNTY-813 preclinical data. In the past three months, Century Therapeutics insiders sold $45,488.00 in company stock, with no insider buying reported. A new major risk identified in February 2026 was shareholder dilution, with an increase in shares outstanding by 111% in the past year. The Annual General Meeting is scheduled for June 11, 2026.

As a clinical-stage biotechnology company, Century Therapeutics, Inc. does not currently have commercially available products, so traditional demand seasonality is not applicable. The company's revenue is primarily derived from strategic collaborations rather than product sales.

Century Therapeutics, Inc. (IPSC) is a clinical-stage biotechnology company focused on developing allogeneic cell therapies for cancer and autoimmune diseases, operating within the biotechnology sector. The company leverages induced pluripotent stem cells (iPSCs) and proprietary Allo-Evasion™ technology to engineer immune cells designed to fight diseases and avoid host immune rejection. Major product candidates include CNTY-813 for type 1 diabetes, CNTY-308 for B-cell-mediated autoimmune diseases, CNTY-101 for B-cell-mediated autoimmune diseases, iPSC-derived αβ T cell products for B-cell malignancies, iPSC-derived γδ T and other non-immune effector cell candidates for hematologic and solid tumors, and iPSC-derived cell therapy candidates for solid tumors.

Century Therapeutics, Inc. is headquartered in Philadelphia, Pennsylvania, with additional locations in Branchburg, New Jersey, and Boston, Massachusetts. It also has a laboratory in Hamilton, Ontario, Canada, focused on glioblastoma, and an innovation hub in Seattle, Washington.

Century Therapeutics maintains a generally positive brand reputation, particularly within the scientific and investment communities focused on biotechnology. The company has received a consensus rating of "Hold" from analysts, with an average rating score of 2.43. Key events contributing to its reputation include a successful private placement, advancement of pipeline programs, scientific recognition, strategic focus, and collaboration revenue.

Century Therapeutics, Inc. has a mixed ownership structure comprising institutional, insider, and public/retail investors. Institutional ownership is significant, with 50.20% of the stock held by institutions. Aktiengesellschaft Bayer holds a substantial 14.67% of the company's shares as of April 2025. Insider shareholders hold approximately 3.48% to 4.37% of the stock.